Nanoparticle formulations are a key tool for addressing drug development challenges, both now and in the future. In this article with PMPS, Nanoform’s Deputy CCO, Sergie Letser, highlights how technological innovation can benefit the industry, from improving bioavailability to satisfying the growing demand for patient-centricity, sustainability and scaled manufacturing.